Patients receiving concurrent chemoradiation for locally advanced head and neck cancer experience severe toxicities that can disrupt treatment and outcomes. In this context, we evaluated the feasibility, acceptability, and usability of a mobile symptom‑monitoring platform during chemoradiation for head & neck cancer.
Find out how the proposed solution for digital symptom monitoring has proven to be feasible, user-friendly, and accepted by both patients and clinicians supporting earlier toxicity recognition and structured self‑management in one of oncology’s most acutely toxic regimens.
